SUMMIT ANNOUNCES THE FIRST PATIENTS DOSED IN PHASE 1B MODIFIED DIET CLINICAL TRIAL OF SMT C1100 FOR TREATMENT OF DMD

Views: 311

Reply to This

Replies to This Discussion

Summit are doing an IPO on Nasdaq next week. As part of that they have a detailed presentation which includes an excellent explanation on DMD and how their drug works.  If your unaware of Utrophin upregulation it's well worth a watch.

http://www.retailroadshow.com/wp/roadshows.asp

Summit now listed on Nasdaq. (SMMT) Raised a further $34m to advance C1100 utrophin drug for DMD through phase 1b and into two phase 2's and fund next generation utrophin modulators coming out of Oxford University (which have a 20x better absorption profile). Prof Kay Davis's work.

Did anyone watch the presentation posted as it gives a very good idea as to why they think Utrophin will work for all DMD boys.

Reply to Discussion

RSS

Need help using this community site? Visit Ning's Help Page.

Members

Events

© 2019   Created by PPMD.   Powered by

Badges  |  Report an Issue  |  Privacy Policy  |  Terms of Service